L. Daniel Browne is CEO & President at Revance Therapeutics, Inc. (RVNC). They have made 15 open-market trades across 1 company since 2014, most recently 2019-06-28.
CIK 0001597583
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $100K since 2014, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RVNC | 152,193 | $556K |
Shares reported on the most recent Form 4, priced at the 2019-07-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RVNC | SELL | 2019-03-18 | 2019-03-19 | $15.51 | $360K | -3.4% | -17.3% | -30.6% |
| RVNC | SELL | 2019-02-19 | 2019-02-20 | $17.68 | $193K | -4.5% | -14.1% | -35.2% |
| RVNC | SELL | 2018-03-15 | 2018-03-16 | $31.55 | $376K | -3.2% | +3.9% | +0.0% |
| RVNC | SELL | 2018-03-07 | 2018-03-09 | $31.43 | $1.7M | -4.1% | -4.3% | -8.5% |
| RVNC | SELL | 2017-11-22 | 2017-11-24 | $24.94 | $190K | +25.8% | +33.5% | +14.8% |
| RVNC | SELL | 2017-10-18 | 2017-10-20 | $26.16 | $401K | +1.0% | -3.7% | +32.1% |
| RVNC | SELL | 2017-09-20 | 2017-09-22 | $23.58 | $179K | +15.5% | +4.8% | +49.6% |
| RVNC | SELL | 2017-08-23 | 2017-08-25 | $22.76 | $1.0M | +11.5% | +8.9% | +15.0% |
| RVNC | SELL | 2017-05-22 | 2017-05-24 | $20.29 | $1.3M | +16.3% | +28.5% | +12.9% |
| RVNC | SELL | 2017-02-22 | 2017-02-24 | $20.57 | $428K | -8.2% | +0.0% | +5.2% |
| RVNC | SELL | 2017-01-25 | 2017-01-27 | $19.78 | $237K | +4.8% | +6.6% | +17.7% |
| RVNC | SELL | 2016-12-28 | 2016-12-30 | $20.94 | $503K | +8.4% | -8.1% | -3.3% |
| RVNC | SELL | 2016-11-25 | 2016-11-25 | $17.89 | $415K | -6.9% | +16.9% | +10.2% |
| RVNC | SELL | 2016-10-26 | 2016-10-28 | $14.85 | $178K | +17.1% | +20.1% | +34.5% |
| RVNC | BUY | 2014-11-28 | 2014-12-01 | $16.67 | $100K | -26.0% | -1.2% | -1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.